Phaseline

Companies › iVascular S.L.U.

iVascular S.L.U.: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 3; Cardiovascular; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
1-month DAPT
Dual antiplatelet therapy (acetylsalicylic acid + prasugrel or ticagrelor) for 1 month, fo
P2RY12, TBXA2RPhase 3Coronary Artery DiseaseJan 2027
Angiolite
Sirolimus-eluting stent with thin-strut cobalt-chromium, open-cell design, durable biostab
MTORPhase 3Coronary Artery DiseaseJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05952206AngiolitePhase 3Coronary Artery DiseaseCardiovascularJan 2027
NCT059522061-month DAPTPhase 3Coronary Artery DiseaseCardiovascularJan 2027

Targets

MTOR (1) P2RY12 (1) TBXA2R (1)

Companies with the same targets

Restorbio Faeth Therapeutics Celcuity Palvella Therapeutics Supernus Pharmaceuticals SAPU NANO (US) Eli Lilly AstraZeneca Jiangsu vcare pharmaceutical technology Viatris Innovation

Companies built like this

Trust Bio-sonics Liquidia Technologies EVD Pharmacy and Medical Company Pulmovant EBI Anti Sepsis

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.